Omeros | OMER - Assets


Omeros reported $200.57M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Adma Biologics USD 732.48M 48.28M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Cytokinetics USD 1.82B 99.77M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Immunic USD 189.74M 165.69M Mar/2026
Insmed USD 2.23B 123.49M Sep/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
MacroGenics USD 345.41M 127.54M Jun/2026
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 34.68B 33.44B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Rockwell Medical USD 52.62M 1.34M Jun/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
United Therapeutics USD 7.03B 186M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026